These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32983297)

  • 21. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity.
    Chance WW; Nguyen QN; Mehran R; Welsh JW; Gomez DR; Balter P; Komaki R; Liao Z; Chang JY
    Pract Radiat Oncol; 2017; 7(3):e195-e203. PubMed ID: 27743801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
    Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
    Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
    Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
    Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
    Iyengar P; Westover K; Timmerman RD
    Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.
    Palma DA; Haasbeek CJ; Rodrigues GB; Dahele M; Lock M; Yaremko B; Olson R; Liu M; Panarotto J; Griffioen GH; Gaede S; Slotman B; Senan S
    BMC Cancer; 2012 Jul; 12():305. PubMed ID: 22823994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgical and ablative therapies for the management of adrenal 'oligometastases' - A systematic review.
    Gunjur A; Duong C; Ball D; Siva S
    Cancer Treat Rev; 2014 Aug; 40(7):838-46. PubMed ID: 24791623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers.
    Kataria T; Naga P; Banerjee S; Gupta D; Narang K; Tayal M; Bisht SS
    South Asian J Cancer; 2021 Apr; 10(2):107-111. PubMed ID: 34568224
    [No Abstract]   [Full Text] [Related]  

  • 30. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SABR-BRIDGE:
    Kidane B; Spicer J; Kim JO; Fiset PO; Abdulkarim B; Malthaner R; Palma D
    Front Oncol; 2020; 10():580189. PubMed ID: 33072612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Local ablative radiotherapy of oligometastatic colorectal cancer].
    Petersen C; Gauer T
    Radiologe; 2017 Feb; 57(2):105-110. PubMed ID: 28054139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure.
    Pasalic D; Lu Y; Betancourt-Cuellar SL; Taku N; Mesko SM; Bagley AF; Chance WW; Allen PK; Tang C; Antonoff MB; Balter PA; Mehran RJ; Welsh JW; Liao Z; Gomez D; Erasmus JJ; Nguyen QN
    Radiother Oncol; 2020 Apr; 145():178-185. PubMed ID: 32044530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.
    Mayinger M; Kotecha R; Sahgal A; Kim MS; Lo SS; Louie AV; Scorsetti M; Slotman B; Guckenberger M
    Lung Cancer; 2023 Aug; 182():107284. PubMed ID: 37390723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic ablative radiotherapy for pulmonary oligometastases and oligometastatic lung cancer.
    Shultz DB; Filippi AR; Thariat J; Mornex F; Loo BW; Ricardi U
    J Thorac Oncol; 2014 Oct; 9(10):1426-33. PubMed ID: 25170641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.
    Olson R; Liu M; Bergman A; Lam S; Hsu F; Mou B; Berrang T; Mestrovic A; Chng N; Hyde D; Matthews Q; Lund C; Glick D; Pai H; Basran P; Carolan H; Valev B; Lefresene S; Tyldesley S; Schellenberg D
    BMC Cancer; 2018 Oct; 18(1):954. PubMed ID: 30286739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The changing role of radiation therapy in the management of oligometastatic disease.
    Tharmalingham H; Hoskin PJ
    Tech Innov Patient Support Radiat Oncol; 2017 Mar; 1():13-15. PubMed ID: 32095538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
    Cruz-Lim EM; Mou B; Baker S; Arbour G; Stefanyk K; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R
    Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):148-156. PubMed ID: 38087705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
    Suh YG; Cho J
    Radiat Oncol J; 2019 Sep; 37(3):149-155. PubMed ID: 31591862
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.